GoldenGolden
Advanced Search
NeuroTronik

NeuroTronik

NeuroTronik is a company that develops neurostimulation therapeutic devices which are designed to treat acute heart failure syndrome.

NeuroTronik is a company that develops neurostimulation therapeutic devices which are designed to treat acute heart failure syndrome. NeuroTronik offers a device which is a cardiac autonomic nerve stimulation that is delivered through a NeuroCathete, placed temporarily in a vein above the heart, in combination with a NeuroModulator, positioned bedside, which results in enhanced cardiac output free of elevated heart rate, allowing physicians to treat patients who are suffering from acute heart failure.

NeuroTronik is in development and investigational clinical use of a novel medical technology approach to help physicians treat heart failure for patients who come to the hospital because of their worsened symptoms.

NeuroTronik seeks to improve clinical outcomes for patients, enhance patient management for physicians, lower hospital admissions, and reduce the rate of patients' return to the hospital within few weeks of discharge.

Timeline

April 2017
NeuroTronik raises a $23,100,000 series B round from Boston Scientific, Hatteras Venture Partners, Lord Baltimore Investment Partners, Mountain Group Capital, Sovereign's Capital and Synergy Life Science Partners.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.